Kailera advances obesity pipeline with positive new data and starts global Phase 3 KaiNETIC trial
Kailera advances obesity pipeline with positive new data and starts global Phase 3 KaiNETIC trial of ribupatide injection
- Unveiled multiple positive new clinical data readouts and trial initiations across its broader obesity pipeline beyond KaiNETIC.
- Said cash on hand, including IPO proceeds, is expected to fund operations into mid-2028.
- Reported first-quarter 2026 results alongside multiple updates across its obesity pipeline for ribupatide injection.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.